换一批Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
第一作者：
Merryn,Voysey
第一单位：
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
作者：
Merryn,Voysey [1]
;
Sue Ann Costa,Clemens [2]
;
Shabir A,Madhi [3]
;
Lily Y,Weckx [4]
;
Pedro M,Folegatti [5]
;
Parvinder K,Aley [1]
;
Brian,Angus [5]
;
Vicky L,Baillie [6]
;
Shaun L,Barnabas [7]
;
Qasim E,Bhorat [8]
;
Sagida,Bibi [1]
;
Carmen,Briner [9]
;
Paola,Cicconi [5]
;
Andrea M,Collins [10]
;
Rachel,Colin-Jones [1]
;
Clare L,Cutland [6]
;
Thomas C,Darton [11]
;
Keertan,Dheda [12]
;
Christopher J A,Duncan [13]
;
Katherine R W,Emary [1]
;
Katie J,Ewer [5]
;
Lee,Fairlie [14]
;
Saul N,Faust [15]
;
Shuo,Feng [1]
;
Daniela M,Ferreira [10]
;
Adam,Finn [16]
;
Anna L,Goodman [17]
;
Catherine M,Green [18]
;
Christopher A,Green [19]
;
Paul T,Heath [20]
;
Catherine,Hill [14]
;
Helen,Hill [10]
;
Ian,Hirsch [21]
;
Susanne H C,Hodgson [5]
;
Alane,Izu [22]
;
Susan,Jackson [5]
;
Daniel,Jenkin [5]
;
Carina C D,Joe [5]
;
Simon,Kerridge [1]
;
Anthonet,Koen [22]
;
Gaurav,Kwatra [14]
;
Rajeka,Lazarus [23]
;
Alison M,Lawrie [5]
;
Alice,Lelliott [1]
;
Vincenzo,Libri [24]
;
Patrick J,Lillie [25]
;
Raburn,Mallory [21]
;
Ana V A,Mendes [26]
;
Eveline P,Milan [27]
;
Angela M,Minassian [5]
;
Alastair,McGregor [28]
;
Hazel,Morrison [5]
;
Yama F,Mujadidi [1]
;
Anusha,Nana [9]
;
Peter J,O'Reilly [1]
;
Sherman D,Padayachee [29]
;
Ana,Pittella [30]
;
Emma,Plested [1]
;
Katrina M,Pollock [31]
;
Maheshi N,Ramasamy [1]
;
Sarah,Rhead [1]
;
Alexandre V,Schwarzbold [32]
;
Nisha,Singh [1]
;
Andrew,Smith [33]
;
Rinn,Song [34]
;
Matthew D,Snape [1]
;
Eduardo,Sprinz [35]
;
Rebecca K,Sutherland [36]
;
Richard,Tarrant [18]
;
Emma C,Thomson [37]
;
M Estée,Török [38]
;
Mark,Toshner [39]
;
David P J,Turner [40]
;
Johan,Vekemans [21]
;
Tonya L,Villafana [21]
;
Marion E E,Watson [5]
;
Christopher J,Williams [41]
;
Alexander D,Douglas [5]
;
Adrian V S,Hill [5]
;
Teresa,Lambe [5]
;
Sarah C,Gilbert [5]
;
Andrew J,Pollard [42]
;
Oxford COVID Vaccine Trial Group
作者单位：
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.
[1]
Institute of Global Health, University of Siena, Siena, Brazil; Department of Paediatrics, University of Oxford, Oxford, UK.
[2]
MRC Vaccines and Infectious Diseases Analytics Research Unit, Johannesburg, South Africa.
[3]
Department of Pediatrics, Universidade Federal de São Paulo, São Paulo, Brazil.
[4]
Jenner Institute, Nuffield Department of Medicine, University of Oxford, UK.
[5]
Respiratory and Meningeal Pathogens Research Unit, University of the Witwatersrand, Johannesburg, South Africa.
[6]
Family Centre for Research with Ubuntu, Department of Paediatrics, University of Stellenbosch, Cape Town, South Africa.
[7]
Soweto Clinical Trials Centre, Soweto, South Africa.
[8]
Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
[9]
Department of Clinical Sciences, Liverpool School of Tropical Medicine and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
[10]
Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK; Department of Infection and Tropical Medicine, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
[11]
Division of Pulmonology, Groote Schuur Hospital and the University of Cape Town, South Africa; Faculty of Infectious and Tropical Diseases, Department of Immunology and Infection, London School of Hygiene & Tropical Medicine, London, UK.
[12]
Department of Infection and Tropical Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK; Translational and Clinical Research Institute, Immunity and Inflammation Theme, Newcastle University, Newcastle upon Tyne, UK.
[13]
Wits Reproductive Health and HIV Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
[14]
NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK.
[15]
School of Population Health Sciences, University of Bristol and University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.
[16]
Department of Infection, Guy's and St Thomas' NHS Foundation Trust, St Thomas' Hospital, London, UK; MRC Clinical Trials Unit, University College London, London, UK.
[17]
Clinical BioManufacturing Facility, University of Oxford, Oxford, UK.
[18]
NIHR/Wellcome Trust Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
[19]
St George's Vaccine Institute, St George's, University of London, London, UK.
[20]
AstraZeneca BioPharmaceuticals, Cambridge, UK.
[21]
VIDA-Vaccines and Infectious Diseases Analytical Research Unit, Johannesburg, South Africa.
[22]
Severn Pathology, North Bristol NHS Trust, Bristol, UK.
[23]
NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, London, UK.
[24]
Department of Infection, Hull University Teaching Hospitals NHS Trust, UK.
[25]
Escola Bahiana de Medicina e Saúde Pública, Salvador, Braziland Hospital São Rafael, Salvador, Brazil; Instituto D'Or, Salvador, Brazil.
[26]
Department of Infectious Diseases, Universidade Federal do Rio Grande do Norte, Natal, Brazil.
[27]
London Northwest University Healthcare, Harrow, UK.
[28]
Setshaba Research Centre, Pretoria, South Africa.
[29]
Department of Internal Medicine, Hospital Quinta D'Or, Rio de Janeiro, Brazil; Instituto D'Or de Pesquisa e Ensino (IDOR), Rio de Janeiro, Brazil; Department of Internal Medicine, Universidade UNIGRANRIO, Rio de Janeiro, Brazil.
[30]
NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK.
[31]
Clinical Research Unit, Department of Clinical Medicine, Universidade Federal de Santa Maria, Santa Maria, Brazil.
[32]
College of Medical, Veterinary & Life Sciences, Glasgow Dental Hospital & School, University of Glasgow, Glasgow, UK.
[33]
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK; Division of Infectious Diseases, Boston Children's Hospital, Boston, MA, USA.
[34]
Infectious Diseases Service, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
[35]
Clinical Infection Research Group, Regional Infectious Diseases Unit, Western General Hospital, Edinburgh, UK.
[36]
MRC-University of Glasgow Centre for Virus Research & Department of Infectious Diseases, Queen Elizabeth University Hospital, Glasgow, UK.
[37]
Department of Medicine, University of Cambridge, UK; Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.
[38]
Heart Lung Research Institute, Department of Medicine, University of Cambridge and Royal Papworth Hospital NHS Foundation Trust, Cambridge, UK.
[39]
University of Nottingham and Nottingham University Hospitals NHS Trust, UK.
[40]
Public Health Wales, Cardiff, Wales; Aneurin Bevan University Health Board, Newport, UK.
[41]
Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. Electronic address: andrew.pollard@paediatrics.ox.ac.uk.
[42]
医学主题词
青少年(Adolescent);成年人(Adult);老年人(Aged);巴西(Brazil);双盲法(Double-Blind Method);女(雌)性(Female);人类(Humans);男(雄)性(Male);中年人(Middle Aged);单盲法(Single-Blind Method);南非(South Africa);治疗结果(Treatment Outcome);青年人(Young Adult)
DOI
10.1016/S0140-6736(20)32661-1
PMID
33306989
发布时间
2025-05-30
- 浏览41
Lancet (London, England)
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
